Biggest Blockbuster Drugs of All Time
Lipitor, Humira and Advair boosted the bottom lines of Big Pharma companies and their shareholders for years.
- (opens in new tab)
- (opens in new tab)
- (opens in new tab)
- Newsletter sign up Newsletter
A prescription drug that surpasses $1 billion in sales is known as a blockbuster. It's a rare feat, but when a pharmaceutical company finds a true blockbuster drug the payoff is enormous. How enormous? Check out the three best-selling prescription drugs of all time.
Blockbuster Drug #1: Lipitor
Company: Pfizer (PFE (opens in new tab))
Treats: High cholesterol
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Lifetime sales: $150.1 billion
Originally developed by Warner-Lambert, Lipitor was approved in the U.S. in 1997. Pfizer acquired its rival in 2000 to gain sole ownership of the cholesterol-fighting drug – and it was well worth it. At one point, Lipitor accounted for one-fourth of Pfizer’s sales. The patent expired in 2011.
Blockbuster Drug #2: Humira
Company: AbbVie (ABBV (opens in new tab))
Treats: Ankylosing spondylitis, arthritis, Crohn’s disease, plaque psoriasis, ulcerative colitis
Lifetime sales: $109.2 billion
Doctors praise Humira’s ability to combat damaging inflammation caused by a number of diseases. Sales will likely peak in 2018 as the drug begins to lose patent protection, but it’s been a heck of a run. Humira is owned by AbbVie, an industry giant that was spun off from Abbott Labs in 2013.
Blockbuster Drug #3: Advair
Company: GlaxoSmithKline (GSK (opens in new tab))
Treats: Chronic obstructive pulmonary disease, asthma
Lifetime sales: $95.7 billion
Advair has been a huge seller since its approval in 2001. And even though its U.S. patent expired in 2010, no successful generic competitor has surfaced. Copying the drug isn’t the problem. Rather, rivals have yet to figure out how to copy the inhaler. Until they do, Glaxo investors can breathe easy.
-
-
Are You Guilty of Financial Infidelity?
Nearly one in four Americans are keeping money-related secrets from their partners.
By Emma Patch • Published
-
IRS Service Improvements Could Bring Faster Tax Refunds
Recent IRS improvements mean taxpayers could see faster tax refunds next year and beyond.
By Katelyn Washington • Published
-
The 9 Best Healthcare Stocks to Buy
The best healthcare stocks offer investors a defensive hedge in an uncertain market.
By Deborah Yao • Published
-
The 12 Best Bear Market ETFs to Buy Now
ETFs Investors who are fearful about the more uncertainty in the new year can find plenty of protection among these bear market ETFs.
By Kyle Woodley • Published
-
9 Best Value Stocks to Buy Now
A roller-coaster year has sent a lot of deserving names into bargain territory. Here are nine value stocks for investors to consider as we head into 2023.
By Jeff Reeves • Published
-
How Big Should My Emergency Fund Be?
Brandon Copeland NFL linebacker and Kiplinger contributing editor Brandon Copeland discusses the importance of building an emergency fund.
By Brandon Copeland • Published
-
Homeowners Insurance: How to Protect Your Home
Brandon Copeland NFL linebacker and Kiplinger contributing editor Brandon Copeland discusses the ins and outs of homeowners insurance.
By Brandon Copeland • Published
-
The 10 Best Stocks for a Bear Market
stocks to buy The ideal bear-market stock pick should have a defensive business, a long history of dividend growth and relatively low volatility. Here are 10 stocks that fit that bill.
By Dan Burrows • Published
-
15 Stocks Warren Buffett Is Buying (And 7 He's Selling)
stocks Berkshire Hathaway CEO Warren Buffett is a bull once more! The Oracle and his team entered eight new positions and added to others in a big way.
By Dan Burrows • Published
-
The "Real" Cost of Buying a Car
Brandon Copeland Atlanta Falcons linebacker and Kiplinger contributing editor Brandon Copeland illustrates how car prices are far more than meets the eye.
By Brandon Copeland • Published